Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ambroxol Soft Pastilles vs Syrup
NCT02572609Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ambroxol in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve from time 0 to last measurable concentration at 48 hours. Started Nov 2011; status: completed.
02
Drugs
ambroxol
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT02572609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572609.